BACKGROUND : A polymorphism upstream of interleukin (IL)-28B was recently identified to be associated with a 2-fold difference in sustained virologic response ( SVR ) to pegylated interferon-alpha and ribavirin therapy in a large cohort of treatment-naive , adherent patients with chronic hepatitis C ( CHC ) virus genotype 1 ( HCV-1 ) infection .